Appili Therapeutics is proud to be at the forefront of global efforts to address emerging biothreats and serious infectious diseases.
Our systematic approach to building a diverse pipeline provides investment opportunities that serve the needs of warfighters, patients, payers, and clinicians. Our strategy centers on identifying emerging biothreats and unmet medical needs, rather than adhering to a specific platform or technology, and matching those needs with potential solutions in the marketplace. This approach provides financial stability and the opportunity to leverage a broad range of government and industry programs, as well as to develop transformative programs that can impact the fundamental treatment landscape for many types of infections.
Capital Raised: $102.9million
Cash and short-term investments: $40,003
| Common shares | 132.4 million |
| Warrants | 41.4 million |
| Options | 7.8 million |
| Fully diluted shares | 181.6 million |
TSX: APLI
Listed June 25, 2019
$0.010-$0.015
52-week low-high
$1.985M
Market cap @ $0.015/share
Bloom Burton & Co. 10.9%